Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Doesn't seem like failure to me
NW Bio Presents Updated Data From DCVax®-Direct Phase I Trial At 5th Annual SMi Cancer Vaccines Conference in London
The top 20% of these patients have so far exceeded 2 years of survival and are still alive. The longest survivor to date has reached nearly 3 years. See Attachment A for details.
The top 30% of these patients (including pancreatic, melanoma, lung, ovarian, sarcoma and other cancers) as a combined group have an average survival to date of 26.7 months, compared with an average of expected survival times of 12.3 months. Individually, these patients have also substantially exceeded their respective expected survival times. See Attachment B for details.
The continuing positive survival results correlate with underlying mechanisms of action and cellular and immune profiles, including phenotype analyses, relative production of a wide range of diverse cytokines by the dendritic cells. Additional positive observations include T-cell infiltration, and PD-L1 expression.
64% of the patients evaluable for PD-L1 checkpoint expression (14 of 22) showed either de novo or significantly increased expression of PD-L1 following DCVax-Direct treatment, indicating potential for combination of DCVax-Direct and checkpoint inhibitors.
The diverse cancers covered in this trial are responsible for approximately 800,000 new cases annually in the US and also at least 800,000 new cases in Europe. When these cancers reach the inoperable metastatic stage, there are no effective treatments available today.
The potential? Does DcVax-Direct not mean anything to you? That's the potential... the treatment of all solid tumors. What more could you want from this cancer treatment platform aside from treating the vast majority of all human cancers?
Tomorrow
Booth at ASCO is another tote-bag nothing burger. It's always possible they could announce at ASCO, and of course anything is possible. However, it won't have anything to do with the size of their booth. "C'mon man! The thing! You know the thing!"(Starts whispering) "TLD is imminent, might happen, might not, ASCO, maybe, or not, but imminent man". The state of NWBO is strong! Now somebody get over here and change my diaper
Anyone have any examples of companies that took 1.5 to 2 years to release PIII trial data after confirmation of data lock? Just curious. Still holding long and strong.
As soon as TLD hits all of this under dollar nonsense will fly away overnight, so much so, that you will think NWBOs chart is the latest SpaceX launch tracker
Appreciate you
I think it's more of a liability + safety issue as most inoperable tumors are located near or close to vital structure(s) where if altered or manipulated may cause serious injury or death. It really doesn't matter about what cool new tool you may have that can remove "more" of it. Then there is also the fact that tumors have a blood supply (bleeding risk could be fatal in certain areas of the brain).
Oh trust me I want it just as bad as you do, JD.
We've been on a steady uptrend since Dec. I think it will stay that way until news but nothing explosive before TLD
How much meth did you smoke before typing this?
Niiiiiice
Very sorry for your loss, Gary
Thanks hmuney
The irony in this post hahahaha! Thank you for the comic relief for the day.
Bravo! Thanks Hbpainter.
Well said.
Because OTC manipulation is easy
We must be super close to TLD because pumpernickel has went pessimist. Cue the Alanis Morissette music.
The FDA fails all the time. One example, Aduhelm. Second example, Vioxx. I could keep going. Ultimately, FDA is government, and one thing I've learned about government? It's grossly inefficient, and decisions unpredictable based on who's paying who behind the scenes
I noticed several folks making share price predictions. Anyone care to make TLD predictions? Curious to see what the board thinks...
Buyout somewhere in 2022 between $33-$35
PR is out
Hear! Hear!
Public forum pal, you make public statements you get public answers...duh?
How many times do lames on this board have to be told they are waiting to release TLD simultaneously with publication? It really isn't that hard to understand. I'll tell you like I told Scotty...TRY TO KEEP UP!
Endpoints changed, trial was halted, and it would be an understatement to say some extraordinary things have taken place over this extensively long trial which deserves a detailed explanation in a publication to explain data (in detail) upon release of TLD (which will maybe be a paragraph or two). There is a method to the madness. I won't hold my breath for you to grasp and comprehend the strategy for a publication, but try to keep up, Scott.
Great post, Umibe
I'm long. Haven't sold. Anecdotal examples by you mean nothing.
Thanks for putting to words what a good bit of us are thinking, skitahoe. Cheers
"Sometime this month or early next month, Advent in Sawston will, IMO, receive gmp certification to make DCVax-l (at an initial pace of 45 batches per month.)"
Will flaskworks eventually double, triple, or even quadruple that 45 batches per month? Trying to grasp the potential impact that flaskworks will eventually have. Any ideas?
Yep, my wife watches all the true crime shows and listens to all the podcasts. Everytime she makes me a drink or plate of food I'm like, "is today the day?". C'mon NWBO, my life depends on you!!
Well said, thank you.
Riiiiight. ??
But the big dip! Buy as much as you can.
Tote-gate 2021
At least $20
And when flaskworks is approved for production we are more likely to meet most demand IMO
Thanks for the uplifting. Some on here need it
Buy the dip, o ye of little faith